KOREA ARLICO PHARM CO.,LTD.
KKRX:2606602,010.00
KRW
-15.00
(-0.74%)
ISIN
KR7260660006
Return %
Stock
S&P 500
1Y
-47.93
14.39
3Y
-64.49
81.42
5Y
-74.69
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hang-Gu Lee
- Full Time Employees
- 228
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Feb 12, 2018
- Website
- arlico.co.kr
- Similar Companies
- Business
- Korea Arlico Pharm Co., Ltd. is a South Korea-based pharmaceutical company primarily engaged in the development, manufacturing, and commercialization of prescription drugs, over-the-counter medicines, and health functional foods, as well as the provision of contract development and manufacturing organization (CDMO) services. Founded in 1992 and headquartered in Seoul, South Korea, the company operates cGMP-compliant manufacturing and research facilities in Jincheon, Chungcheongbuk-do. Korea Arlico Pharm Co., Ltd. serves medical institutions, pharmacies, healthcare distributors, and corporate partners across domestic and international markets. The company provides a broad portfolio of pharmaceutical products and healthcare solutions organized across key therapeutic areas and operational segments, including: circulatory and cardiovascular agents comprising antihypertensives, lipid-regulating agents, and combination statin therapies; central nervous system medications, including cognitive enhancers and treatments for neurodegenerative disorders such as choline alfoscerate and donepezil formulations; digestive and gastrointestinal treatments including proton pump inhibitors, gastritis therapeutics, and gastrointestinal motility regulators; musculoskeletal and anti-inflammatory medications comprising nonsteroidal anti-inflammatory drugs, anti-arthritic agents, and muscle relaxants; respiratory and antihistamine products for asthma, bronchitis, and allergic rhinitis; metabolic disease therapies targeting diabetes and osteoporosis; over-the-counter consumer health products such as multivitamin complexes, liver protection formulations, analgesics, and topical ointments; health functional foods and dietary supplements targeting general wellness, immunity, and joint health; and contract manufacturing and development services encompassing formulation research, regulatory support, toll manufacturing, and packaging for solid oral dosages, liquid forms, and specialized soft capsules. In recent developments, Korea Arlico Pharm Co., Ltd. has advanced its operational infrastructure by completing smart factory upgrades and production line expansions at its Jincheon manufacturing complex, thereby enhancing its production efficiency and expanding capacity for large-scale CMO and CDMO contracts. The company has also expanded its research and development initiatives toward incrementally modified drugs and multi-compound combination therapies for chronic cardiovascular and metabolic conditions. Furthermore, Korea Arlico Pharm Co., Ltd. has established strategic co-promotion and commercial partnerships with domestic biotechnology firms to co-develop novel drug delivery systems and broaden clinic-level distribution networks, while accelerating international market registrations and export agreements across Southeast Asia, Central Asia, and Latin America to drive overseas business expansion.